Drug Profile
C 12
Alternative Names: C-12Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Pharma Bio LLC
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in Russia (unspecified route)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Russia
- 01 Mar 2016 Preclinical trials in Alzheimer's disease in Russia (unspecified route) before March 2016